Emergent Biosolutions Inc (EBS)
$9.13
$0.03
(0.33%)
As on 07-May-2026 16:15EDT
Market cap
$470 Mln
Revenue (TTM)
$677 Mln
P/E Ratio
--
P/B Ratio
0.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-15 Mln
-
ROE
-0 %
-
ROCE
-- %
-
Industry P/E
26.31
-
EV/EBITDA
5.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
51,800,000
10 Years Aggregate
CFO
$1,437.10 Mln
EBITDA
$1,798.94 Mln
Net Profit
$428.88 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Emergent Biosolutions Inc (EBS)
| -26.1 | 12.7 | -13.4 | 90.6 | 0.6 | -31.6 | -12.9 |
|
BSE Sensex*
| -8.6 | 3.8 | -7.4 | -4.1 | 8.2 | 9.5 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Emergent Biosolutions Inc (EBS)
| 29.3 | 293.9 | -79.7 | -72.8 | -51.5 | 66.1 | -9.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Emergent Biosolutions Inc (EBS)
|
9.1 | 469.5 | 676.8 | -15.4 | 9.0 | -- | -- | 0.8 |
| 13.7 | 4,344.8 | 2,323.3 | 137.9 | 12.3 | -- | 61.9 | 105.4 | |
| 15.1 | 201.2 | 116.3 | -11.1 | -10.5 | -7.9 | -- | 1.5 | |
| 0.5 | 21.4 | 4.2 | -3.6 | -55.0 | -0 | -- | 0.9 | |
| 51.1 | 5,598.4 | 769.1 | 47.9 | 5.4 | 7.5 | 149 | 8.6 | |
| 3.1 | 1,150.8 | 839.3 | -57.5 | -2.3 | -7.1 | -- | 1.4 | |
| 8.1 | 5,723.6 | 7,682.7 | 438.7 | 15.9 | 7.5 | 12.2 | 0.9 | |
| 0.1 | 107.0 | 0.0 | -17.4 | -- | -- | -- | 14.4 | |
| 26.7 | 1,420.7 | 61.4 | -166.2 | -267.6 | -- | -- | 49.0 | |
| 23.6 | 932.2 | 734.9 | 9.3 | 2.6 | 1.3 | 182.2 | 1.5 |
Shareholding Pattern
View DetailsAbout Emergent Biosolutions Inc (EBS)
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through... Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. Address: 300 Professional Drive, Gaithersburg, MD, United States, 20879 Read more
-
Executive VP, CFO & Treasurer
Mr. Richard S. Lindahl M.B.A.
-
Executive VP, CFO & Treasurer
Mr. Richard S. Lindahl M.B.A.
-
Headquarters
Gaithersburg, MD
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Emergent Biosolutions Inc (EBS)
What is the current share price of Emergent Biosolutions Inc (EBS) Today?
The share price of Emergent Biosolutions Inc (EBS) is $9.13 (NYSE) as of 07-May-2026 16:15 EDT. Emergent Biosolutions Inc (EBS) has given a return of 0.63% in the last 3 years.
What is the current PB & PE ratio of Emergent Biosolutions Inc (EBS)?
Since, TTM earnings of Emergent Biosolutions Inc (EBS) is negative, P/E ratio is not available.
The P/B ratio of Emergent Biosolutions Inc (EBS) is 0.84 times as on 07-May-2026, a 86 discount to its peers’ median range of 5.84 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
12.31
|
1.24
|
|
2024
|
-2.72
|
1.07
|
|
2023
|
-0.16
|
0.19
|
|
2022
|
-2.79
|
0.42
|
|
2021
|
10.60
|
1.44
|
What is the 52 Week High and Low of Emergent Biosolutions Inc (EBS)?
The 52-week high and low of Emergent Biosolutions Inc (EBS) are Rs 14.06 and Rs 4.72 as of 08-May-2026.
What is the market cap of Emergent Biosolutions Inc (EBS)?
Emergent Biosolutions Inc (EBS) has a market capitalisation of $ 470 Mln as on 07-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Emergent Biosolutions Inc (EBS)?
Before investing in Emergent Biosolutions Inc (EBS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.